None listed
Conditions
Brief summary
This project aims to examine the acceptability of new treatments for health anxiety in a medical outpatient setting. It will also link participant data to NSW Health records to examine trends in hospital usage. The study can be broken into three parts. Screening (Step-1) - patients attending one of four clinics at the Prince of Wales Hospital asked to complete digital screening for health anxiety. We hypothesise that: 1. Digital screening for anxiety will be acceptable to medical outpatients. 2. Between 20-25% of medical outpatients will have elevated anxiety scores. SHAPE Pilot (Step-2)- those who are identified to have elevated health anxiety will be called by a researcher and invited to partake in an iCBT intervention or intervention with a clinician. Follow-up measures will be taken at 6, 12, and 24 weeks to monitor the effect of the interventions. We hypothesise that: 1. The novel care pathway for health anxiety will be acceptable. 2. The novel care pathway for health anxiety will result in a reduction in health anxiety measures. Data linkage- We will collaborate with the Centre for Health Record Linkage (CHeReL), to link participant data to data regarding health care utilisation. This will be used to examine relationships between health anxiety and health care utilisation. We hypothesise that group level data linkage will show: 1. Higher rates of health care utilisation according to health anxiety self-report measures. 2. Concordance between actual and self-reported rates of health care utilisation in general.
Interventions
During Step-1, participants at selected outpatient clinics will be asked to complete an online survey via an SMS link. This survey will include self-report measures of health anxiety and general anxiety, and will take approximately 5 minutes. Those who score high on the health anxiety measure (Whitely Index-6 score =>18) will be offered follow-up contact to discuss treatment options. Those who accept will be offered access to treatment (Step-2), and will be able to choose either an internet cognitive-behavioural therapy (iCBT) course or access to a new face-to-face clinic. As this is a pilot study, with an aim to determine the acceptability of treatment options, participants will not be randomised, but will rather be able to engage in their preferred treatment. Those who participate in iCBT will be given access to This Way Up's Health Anxiety course (https://thiswayup.org.au/courses/the-health-anxiety-course/), developed by St Vincent's Hospital. This is a validated iCBT course that has been shown to be effective in managing health anxiety. This Way Up features 6 online sessions (presented as story-based slide shows), lasting approximately 1-hour, over a 12-week period, and will require some work from participants between sessions. The sessions will in turn cover information about health anxiety, reducing focus on worries, awareness of anxious thoughts, putting thoughts/fears to the test, tackling avoidance/safety behaviours, and staying well. “Homework” is provided as downloadable documents, and typically involves the applying skills and techniques learned in the sessions in the individual’s life. Throughout the program, they will have access to a clinician via email and phone. No limit is placed on how often they may contact the clinician. Adherence will be monitored using data such as number of sessions completed. Those who participate in our face-to-face program will meet with a member of the SHAPE psychiatry team to determine a treatment plan. This plan will be personalised to the participant, with the participant and clinician working together to discuss all options, as well as the pros and cons for each treatment in their specific case. This plan could feature treatments such as psychotherapy, medication, exercise physiology and social worker support. Note that this program is not testing new medications; any medications prescribed will be chosen based on clinical best-practice and used only where appropriate. Participants will engage in a minimum of one 1-hour session, with three sessions as the expected number. Number of sessions with other treatments will be determined as part of clinical review, as per best practice. Adherence will be monitored by tracking whether people return to planned follow-up appointments. Participants in Step-2 will be asked to complete online assessments (Whitely Index-6, General Anxiety Disorder-7, Patient Health Questionnaire-9, Patient Health Questionnaire-15; EuroQoL-5 Dimensions, Social Functioning Questionnaire, Credibility/Expectancy Questionnaire, Treatment Satisfaction Questionnaire, Standardised Assessment of Personality - Abbreviated Scale at 0-weeks, 6-weeks, 12-weeks and 24-weeks (follow-up). The cumulative time to complete these assessments is expected to be up to 20 minutes per time-period. Additional assessments will be administered for those attending the face-to-face clinic, including The Montreal Cognitive Assessment, Anxiety and related disorders interview schedule for DSM-5, an intrusive thoughts assessment and a semi-structured qualitative assessment of the clinic. These assessments will form part of the initial session, which may take up to 90 minutes in total.
Sponsors
Study design
Eligibility
Inclusion criteria
Step-1 (Screening): The study will be made available to: - All adult (equal to or greater than 18 years old) attendees at four specified clinics (dermatology, rheumatology, endocrinology, and Upper GI surgery). - Physical health: attendees to the assigned outpatient clinics. - Willing to give electronic informed consent. - Understand spoken and written English. There is no specific laboratory, radiological or other investigation parameters. Step-2 (SHAPE Pilot): - Meet criteria for Part 1. - Completion of full screening. - WI-6 score of 18+. - Agree (opt in) to having further contact, or later contacts us to request involvement. - Willing to participate with study schedule. - Provides verbal ongoing consent when contacted. - Provides home address. - Is eligible for Medicare. Part 3 (Data (record) linkage): - Meet inclusion criteria for Part 1.
Exclusion criteria
Step-1 (Screening): - Has participated in the trial within the past 3 months (to avoid duplication).